Medicare will soon launch a pilot program that will test the use of AI to automate the prior authorization process—a tool that will recommend whether to approve or deny coverage for a patient in the program.
The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?
